Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
brain cancer
Pharma
Servier rounds out rare cancer offerings with $2.5B Day One buy
Servier has unveiled a deal to acquire commercial-stage Day One Biopharmaceuticals and its med Ojemda for $21.50 per share in cash.
Fraiser Kansteiner
Mar 6, 2026 10:14am
Servier revenue growth hits 16% as group eyes €10B 2030 goal
Jan 27, 2026 10:55am
On heels of M&A deal, Jazz scores new FDA nod
Aug 6, 2025 3:26pm
In a first, FDA approves Servier's Voranigo in low-grade gliomas
Aug 6, 2024 5:25pm
Day One pressures Novartis with FDA nod for novel RAF inhibitor
Apr 23, 2024 10:13pm
Deal tees up delivery of oncolytic viruses to brain using robots
Dec 21, 2021 8:40am
